Cromolyn as a novel pharmacophore of the Zα domain of the RNA ‐editing enzyme ADAR1p150
Protein Science · 2025-11 · 34 (11)
DOI: 10.1002/pro.70341 ↗At a glance
Journal article in Protein Science, published online on 2025-10-11. Written by Nicolas Langdon and 7 co-authors. Institution: Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Major MEDLINE topics: Adenosine Deaminase, RNA-Binding Proteins, RNA Editing. Cited 1 times so far (Crossref); 23 references. The full text is freely available in PubMed Central. Funded by: NIH HHS, NSF, NIGMS NIH HHS.
Abstract (original language)
ADAR1p150 is a critical RNA‐editing enzyme for maintaining cellular homeostasis through dsRNA binding, protein–protein interactions, and adenosine‐to‐inosine (A‐to‐I) editing. Beyond its dsRNA binding domains, ADAR1p150 contains a Zα domain that can induce a conformational switch of dsDNA and dsRNA from stable B/A forms to a higher‐energy left‐handed Z form. By stabilizing Z‐RNA, ADAR1p150 is thought to modulate immune activation by competing with dsRNA sensors like MDA5 and ZBP1. ADAR1p150's editing activity minimizes dsRNA's presence and prevents dsRNA‐mediated inflammatory pathways' activation. Our study employs NMR to introduce a novel pharmacophore model for Zα domain binders. We identify cromoglicic acid, also known as the FDA‐approved drug cromolyn, as an ADAR1 Zα binder that competes with nucleic acid recognition. Cromolyn does not bind to ZBP1 Zα domains, which are the only other human Zα domains. Our work paves the way for effectively modulating ADAR1p150 function with small molecules, opening new avenues for enhancing anti‐cancer immune responses.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- College of Health Sciences and Technology, Rochester Institute of Technology, Rochester, New York, USA.
- Department of Immunology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, Texas, USA.
ORCID profiles: Nicolas Langdon, Charles Kroft, Jeffrey Krall, Mercedes Rincon, Beat Vögeli, Quentin Vicens, Morkos A Henen
Funding
- NIH HHS
- NSF
- NIGMS NIH HHS
- NIAID NIH HHS
- NMR Structural Biology Shared Resource Facility
- NCI NIH HHS
- National Institutes of Health
- Cancer Center, University of Colorado
Cite
APA
Langdon, N., Kroft, C., Fang, Q., Krall, J., Rincon, M., Vögeli, B., Vicens, Q., & Henen, M. A. (2025). Cromolyn as a novel pharmacophore of the Zα domain of the RNA ‐editing enzyme ADAR1p150. Protein Science, 34(11). https://doi.org/10.1002/pro.70341
Vancouver
Langdon N, Kroft C, Fang Q, Krall J, Rincon M, Vögeli B, et al. Cromolyn as a novel pharmacophore of the Zα domain of the RNA ‐editing enzyme ADAR1p150. Protein Science. 2025;34(11). doi:10.1002/pro.70341
BibTeX
@article{Langdon2025,
author = {Langdon, Nicolas and Kroft, Charles and Fang, Qian and Krall, Jeffrey and Rincon, Mercedes and Vögeli, Beat and Vicens, Quentin and Henen, Morkos A},
title = {Cromolyn as a novel pharmacophore of the Zα domain of the RNA ‐editing enzyme ADAR1p150},
journal = {Protein Science},
year = {2025},
volume = {34},
number = {11},
doi = {10.1002/pro.70341}
}
EUVIMED